DrugPatentWatch Database Preview

ERIVEDGE Drug Profile

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

When do Erivedge patents expire, and what generic alternatives are available?

Erivedge is a drug marketed by Genentech and is included in one NDA. There are two patents protecting this drug.

This drug has forty-nine patent family members in twenty-four countries.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this compound. Additional details are available on the vismodegib profile page.

US ANDA Litigation and Generic Entry Outlook for Erivedge

Erivedge was eligible for patent challenges on January 30, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 11, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ERIVEDGE

International Patents:	49
US Patents:	2
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	104
Clinical Trials:	40
Patent Applications:	66
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for ERIVEDGE
DailyMed Link:	ERIVEDGE at DailyMed

See drug prices for ERIVEDGE

Generic Entry Opportunity Date for ERIVEDGE

NDA:

203388

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ERIVEDGE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Columbia University	Phase 2
University Hospital, Bordeaux	Phase 4
University Hospital Heidelberg	Phase 1/Phase 2

See all ERIVEDGE clinical trials

Pharmacology for ERIVEDGE

Drug Class	Hedgehog Pathway Inhibitor
Mechanism of Action	Smoothened Receptor Antagonists

Synonyms for ERIVEDGE

085G559

2-Chloranyl-~{n}-(4-Chloranyl-3-Pyridin-2-Yl-Phenyl)-4-Methylsulfonyl-Benzamide

2-chloro-n-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)benzamide

2-Chloro-N-(4-chloro-3-(2-pyridl)phenyl)-4-(methylsulfonyl)benzamide

2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methyl sulfonyl)benzamide

2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide

2-chloro-N-(4-chloro-3-pyridin-2-yl-phenyl)-4-methanesulfonyl-benzamide

2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide

2-CHLORO-N-[4-CHLORO-3-(2-PYRIDINYL)PHENYL]-4-(METHYLSULFONYL)-BENZAMIDE

2-Chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)benzamide

2-chloro-N-[4-chloro-3-(2-pyridyl)phenyl]-4-methylsulfonyl-benzamide

2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-

2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide

2-chloro-N~1~-[4-chloro-3-(2-pyridyl)phenyl]-4-(methylsulfonyl)benzamide

25X868M3DS

4CA-1325

879085-55-9

A10467

AB0008125

AB01565813_02

ABP000894

AC-26969

AJ-103831

AK-77261

AKOS015966534

AN-471

ANW-60962

AOB1040

AS-14066

AX8167197

BC660083

BCP01715

BCP9000713

BCPP000223

BDBM50249522

Benzamide, 2-chloro-N-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)-

BG0661

BPQMGSKTAYIVFO-UHFFFAOYSA-N

C19H14Cl2N2O3S

C538724000

CHEBI:66903

CHEMBL473417

CS-0255

CTK8B8648

CUR-691

D09992

DB08828

DTXSID40236689

Erivedge (TN)

EX-A2178

FT-0675833

GD 0449|||2-Chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)benzamide

GDC 0449

GDC-0449

GDC-0449 - Selumetinib

GDC-0449 (Vismodegib)

GDC-0449, GDC0449, GDC 0449, 879085-55-9

GDC-0449,Vismodegib

GDC-0449,Vismodegib, HhAntag691

GDC-0449(Vismodegib)

GDC-0449(Vismodegib)/GDC0449

GDC-449

GDC0449

GTPL6975

Hh-Antag691

HhAntag691

HMS3604K16

HMS3654E17

HSDB 8130

HY-10440

J-509076

J90022

KB-308771

KB-81450

KS-000000BH

MCULE-6680076172

methanesulfonylbenzamide

MLS006012035

MolPort-009-679-417

NCGC00242497-01

NCGC00242497-02

NCGC00242497-06

NSC 747691

NSC-747691

NSC-755986

NSC747691

NSC755986

PB15086

PubChem19137

Q-2305

QCR-40

R 3616

R-3616

RG-3616

RL05479

s1082

SC-87729

SCHEMBL302587

SMR004703564

SR-01000941574

SR-01000941574-1

ST24040458

SW218087-2

TC-149707

UNII-25X868M3DS

V-4050

VIS

Vismodegib

Vismodegib (GDC-0449)

Vismodegib (USAN/INN)

Vismodegib [USAN:INN]

Vismodegib, free base

Vismodegib; GDC-0449

Vismodegib; HhAntag 691

vismodegibum

X4669

ZINC40899447

US Patents and Regulatory Information for ERIVEDGE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genentech	ERIVEDGE	vismodegib	CAPSULE;ORAL	203388-001	Jan 30, 2012		RX	Yes	Yes
Genentech	ERIVEDGE	vismodegib	CAPSULE;ORAL	203388-001	Jan 30, 2012		RX	Yes	Yes			Y	Y

International Patents for ERIVEDGE

Country	Patent Number	Estimated Expiration
South Korea	20170001725
New Zealand	589385
Denmark	1789390
China	101072755
European Patent Office	1789390

Supplementary Protection Certificates for ERIVEDGE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1789390	50/2013	Austria		PRODUCT NAME: VISMODEGIB; REGISTRATION NO/DATE: EU/1/13/848 (MITTTEILUNG) 20130717
1789390	C01789390/01	Switzerland		PRODUCT NAME: VISMODEGIB; REGISTRATION NO/DATE: SWISSMEDIC 62497 30.05.2013
1789390	170 12-2013	Slovakia		PRODUCT NAME: VISMODEGIB; REGISTRATION NO/DATE: EU/1/13/848/001 20130712
1789390	1390057-6	Sweden		PERIOD OF VALIDITY (FROM - UNTIL): 2025-09-03 - 2028-07-16
1789390	2013C/071	Belgium		PRODUCT NAME: VISMODEGIB; AUTHORISATION NUMBER AND DATE: EU/1/13/84/001 20130715